WuXi Biologics, a China-based contract research, development, and manufacturing organisation (CRDMO) in China, has announced the launch of its newest platform, EffiX.
This proprietary technology utilises an E. coli expression system designed to optimise the yield and stability of recombinant proteins and plasmid DNA production.
According to WuXi Biologics, the global market for microbial-derived products is experiencing significant growth. This is driven by the rising demand for complex biomolecules such as antibody fragments, nanobodies, enzymes, cytokines, antigens, polypeptides, and plasmid DNA (pDNA).
These components are pivotal in the development of advanced therapies. WuXi Biologics aims to address existing production challenges with the EffiX platform, which facilitates high-yield manufacturing of microbial-derived biologics. The platform achieves titers surpassing 15 g/L for non-mAb recombinant proteins and more than 1g/L for plasmid DNA.
WuXi Biologics CEO Chris Chen said: “We are excited to upgrade our microbial solutions with the innovative EffiX platform, which offers our clients exceptional productivity and product quality, along with scalability and flexibility at every stage of development.
“WuXi Biologics’ continual launching of new technology platforms stems from our drive to push boundaries and foster innovation – all with the goal of enabling our global partners to accelerate the delivery of more high-quality and affordable biologics to patients worldwide.”
EffiX is tailored to streamline processes across various project stages, from research to commercial production. It accelerates biotherapeutic advancements by offering a comprehensive and cost-efficient chemistry, manufacturing, and controls (CMC) strategy.
The platform is a critical element within WuXi Biologics’ broader technology suite focused on microbial expression systems. This integrated approach covers early-stage research, CMC development, and GMP manufacturing, promoting faster and more efficient production processes for next-generation therapy modalities.
In January 2025, WuXi Biologics entered into an agreement with Candid Therapeutics, a biotechnology firm specialising in T-cell engagers for autoimmune and inflammatory diseases.
Under this agreement, Candid Therapeutics gains exclusive global rights to a preclinical trispecific T-cell Engager from WuXi Biologics’ multispecific antibody platform WuXiBody. The partnership entitles WuXi Biologics to receive up to $925m through upfront payments and developmental and sales milestones, along with royalties.
